Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

• Published in: Frontiers in pharmacology Vol. 11
• Main Authors: Sarkar, Chandan, Mondal, Milon, Torequl Islam, Muhammad, Martorell, Miquel, Docea, Anca Oana, Maroyi, Alfred, Sharifi-Rad, Javad, Calina, Daniela
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 15-09-2020
• Subjects: convalescent plasma; COVID-19 proposed therapy; pandemic; Pharmacology; Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); therapeutic challenges
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2020.572870

The COVID-19 pandemic represents an unprecedented challenge for the researchers to offer safe, tolerable, and effective treatment strategies for its causative agent known as SARS-CoV-2. With the rapid evolution of the pandemic, even the off-label use of existing drugs has been restricted by limited availability. Several old antivirals, antimalarial, and biological drugs are being reconsidered as possible therapies. The effectiveness of the controversial treatment options for COVID-19 such as nonsteroidal antiinflammatory drugs, angiotensin 2 conversion enzyme inhibitors and selective angiotensin receptor blockers was also discussed. A systemic search in the PubMed, Science Direct, LitCovid, Chinese Clinical Trial Registry, and ClinicalTrials.gov data bases was conducted using the keywords “coronavirus drug therapy,” passive immunotherapy for COVID-19’, “convalescent plasma therapy,” (CPT) “drugs for COVID-19 treatment,” “SARS-CoV-2,” “COVID-19,” “2019-nCoV,” “coronavirus immunology,” “microbiology,” “virology,” and individual drug names. Systematic reviews, case presentations and very recent clinical guidelines were included. This narrative review summarizes the available information on possible therapies for COVID-19, providing recent data to health professionals.